385 related articles for article (PubMed ID: 14729746)
1. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of moxifloxacin in a murine model of severe systemic mixed infection with Escherichia coli and Bacteroides fragilis.
Eckhardt C; Fickweiler K; Schaumann R; Ackermann G; Rodloff AC
Anaerobe; 2003 Aug; 9(4):157-60. PubMed ID: 16887704
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
5. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis.
Huelves L; Gracia M; Del Prado G; Rodríguez-Cerrato V; Martínez-Marín C; Ponte C; Soriano F; Coronel P; Gimeno M; Blanco J
Int J Antimicrob Agents; 2006 Aug; 28(2):151-3. PubMed ID: 16815688
[No Abstract] [Full Text] [Related]
8. Intravenous injection of mice with bacteroides fragilis and Escherichia coli: role of Thioglycollate medium in the infectious process.
Rodloff AC; Rodloff S; Fischer B; Hahn H
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 May; 254(3):405-12. PubMed ID: 6372324
[TBL] [Abstract][Full Text] [Related]
9. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
Brook I; Ledney GD
J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
[TBL] [Abstract][Full Text] [Related]
11. [Study of the efficacy and tolerance of imipenem-cilastatin used as monotherapy for the adjuvant treatment to surgery of peritonitis. Results of a French multicenter study including 257 patients].
Midy D; Pometan JP; Baste JC; Pajadon V
J Chir (Paris); 1992; 129(6-7):303-8. PubMed ID: 1474112
[TBL] [Abstract][Full Text] [Related]
12. Low endotoxin release from Escherichia coli and Bacteroides fragilis during exposure to moxifloxacin.
Trautmann M; Scheibe C; Wellinghausen N; Holst O; Lepper PM
Chemotherapy; 2010; 56(5):364-70. PubMed ID: 20926860
[TBL] [Abstract][Full Text] [Related]
13. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
15. The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation.
Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
Am Surg; 1995 Aug; 61(8):726-31. PubMed ID: 7618816
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of the liver and biliary tract to anaerobic infection in extrahepatic biliary tract obstruction. III. Possible synergistic effect between anaerobic and aerobic bacteria. An experimental study in rabbits.
Lykkegaard Nielsen M; Asnaes S; Justesen T
Scand J Gastroenterol; 1976; 11(3):263-72. PubMed ID: 775613
[TBL] [Abstract][Full Text] [Related]
19. Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
Brook I; Germana A; Giraldo DE; Camp-Hyde TD; Bolduc DL; Foriska MA; Elliott TB; Thakar JH; Shoemaker MO; Jackson WE; Ledney GD
J Antimicrob Chemother; 2005 Dec; 56(6):1074-80. PubMed ID: 16239289
[TBL] [Abstract][Full Text] [Related]
20. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
